Alessio Mazzieri

Perugia, 06012, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Aldosterone synthase inhibitors in hypertension and chronic kidney disease: double the benefit?

Aldosterone synthase inhibitors in hypertension and chronic kidney disease: double the benefit?

Journal: Current opinion in nephrology and hypertension

Published: March 12, 2026

Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study.

Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study.

Journal: Diabetes, obesity & metabolism

Published: December 02, 2025

Nephroprotective Mechanisms of SGLT2i: Beyond the Glucose-Lowering Effect.

Nephroprotective Mechanisms of SGLT2i: Beyond the Glucose-Lowering Effect.

Journal: Biomedicines

Published: July 26, 2025

Switching from insulin injections to degludec/liraglutide in older frail persons: 6-month body composition remodelling.

Switching from insulin injections to degludec/liraglutide in older frail persons: 6-month body composition remodelling.

Journal: European geriatric medicine

Published: April 19, 2025

The impact of ideglira in treatment simplification in older adults with type 2 diabetes mellitus already on insulin therapy: The stop study.

The impact of ideglira in treatment simplification in older adults with type 2 diabetes mellitus already on insulin therapy: The stop study.

Journal: Diabetes research and clinical practice

Published: January 26, 2025

Treatment of hypertension in the elderly: target the lowest well-tolerated blood pressure.

Treatment of hypertension in the elderly: target the lowest well-tolerated blood pressure.

Journal: Expert review of cardiovascular therapy

Published: November 07, 2024

Changes in 24-hour blood pressure profile after 12 weeks of dapagliflozin treatment in patients with diabetic kidney disease: an Italian multicenter prospective study.

Changes in 24-hour blood pressure profile after 12 weeks of dapagliflozin treatment in patients with diabetic kidney disease: an Italian multicenter prospective study.

Journal: Clinical kidney journal

Published: September 13, 2024

Aldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?

Aldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?

Journal: Kidney & blood pressure research

Published: July 16, 2024

Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.

Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.

Journal: International journal of molecular sciences

Published: February 29, 2024

Diabetes-Alzheimer's connection in older age: SGLT2 inhibitors as promising modulators of disease pathways.

Diabetes-Alzheimer's connection in older age: SGLT2 inhibitors as promising modulators of disease pathways.

Journal: Ageing research reviews

Published: June 23, 2023

The role of gastric emptying in glucose homeostasis and defense against hypoglycemia: Innocent bystander or partner in crime?

The role of gastric emptying in glucose homeostasis and defense against hypoglycemia: Innocent bystander or partner in crime?

Journal: Diabetes research and clinical practice

Published: April 09, 2023

GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway.

GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway.

Journal: Frontiers in immunology

Published: February 10, 2023

Showing 1-12 of 14

Last Updated: 09/26/2026